Trial Profile
A single center clinical study of EGFR/HER2 targeted inhibitor Lapatinib in the treatment of refractory Cushing's disease
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2017
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Cushing syndrome
- Focus Therapeutic Use
- 21 Jun 2017 New trial record